Mechanism of action Hypophosphatasia is caused by a genetic defect of tissue-nonspecific alkaline phosphatase (TNSALP), an enzyme that plays a role in bone mineralization.<unk>  is a recombinant glycoprotein that contains the catalytic domain (the active site) of TNSALP. It is thus a form of enzyme replacement therapy. Pharmacokinetics After subcutaneous injection,<unk>  has a bioavailability of 46–98% and reaches highest blood plasma concentrations after 24 to 48 hours. Elimination half life is five days.
Asfotase alfa
Velmanase alfa
Sebelipase alfa
Angiozyme
Desmoteplase
Anistreplase
Lusutrombopag
Celadrin 